What insurance policy changes affect CPT 38207?

There are 6 tracked policy changes affecting CPT 38207, including updates from Anthem BCBS, CareSource, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 38207?

Payers that have issued tracked updates for CPT 38207 include: Anthem BCBS, CareSource, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 38207 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 38207. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 38207?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

38207 — Freezing and storing stem cells for potential future medical use or research purposes.: Insurance Policy Changes

38207 Insurance Policy Changes

CPT 38207, in plain terms, covers Freezing and storing stem cells for potential future medical use or research purposes. CPT 38207 is referenced in 6 tracked payer policy changes from Anthem BCBS, CareSource, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 38207 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Betibeglogene Autotemcel (Zynteglo) (CPB 1016, reviewed 2025-12-31)

Aetna·Effective Dec 31, 2025

Aetna has issued a new clinical policy (CPB 1016, effective 2025-12-31) establishing coverage criteria for Betibeglogene Autotemcel (Zynteglo), a gene therapy for transfusion-dependent beta-thalassemia. The policy requires precertification through National Medical Excellence (NME) and mandates administration at Aetna Institutes GCIT Network facilities. Coverage is limited to patients age 4+ with specific genotypes, transfusion history, and HLA-matched donor ineligibility, with numerous exclusionary medical conditions.

38207 Insurance Policy Changes

[New York] Precertification/prior authorization requirement changes

[Georgia] Prior Authorization Requirement Update

Bendamustine Products (CPB 0875, reviewed 2026-02-24)

Betibeglogene Autotemcel (Zynteglo) (CPB 1016, reviewed 2025-12-31)

Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia

Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas